GLRX2 and cancer: Based on the results of pan-cancer analysis, we found that GLRX2, NMT1, PPP2R2B and TRAF3IP3 exhibited a dysregulated level in many types of tumors, highlighting their potential roles in tumor progression (Fig. 3C–F).